View Older Stories View More Recent Stories

Jun 9, 2020 12:00PM OSE Immunotherapeutics Identifies Monoclonal Antibody Antagonists of CLEC-1 as New Checkpoint Inhibitors of Immune Myeloid Cells in Immuno-Oncology
Jun 9, 2020 12:00PM OSE Immunotherapeutics Identifies Monoclonal Antibody Antagonists of CLEC-1 as New Checkpoint Inhibitors of Immune Myeloid Cells in Immuno-Oncology
May 27, 2020 12:00PM OSE Immunotherapeutics Announces Procedures for Virtual Combined General Meeting
May 27, 2020 12:00PM OSE Immunotherapeutics Announces Procedures for Virtual Combined General Meeting
May 26, 2020 01:30AM OSE Immunotherapeutics Signs €7 Million Non-Dilutive Loan Agreement Guaranteed by the French State
May 26, 2020 01:30AM OSE Immunotherapeutics Signs €7 Million Non-Dilutive Loan Agreement Guaranteed by the French State
May 18, 2020 01:30AM OSE Immunotherapeutics Presents CLEC-1, Novel Myeloid Immune Checkpoint Target for Cancer Immunotherapy, Oral Presentation at AACR Virtual Meeting II 2020 – June 22-24
May 18, 2020 01:30AM OSE Immunotherapeutics Presents CLEC-1, Novel Myeloid Immune Checkpoint Target for Cancer Immunotherapy
May 5, 2020 12:00PM OSE Immunotherapeutics Announces COVID-19 Prophylactic Vaccine Program
May 5, 2020 12:00PM OSE Immunotherapeutics Announces COVID-19 Prophylactic Vaccine Program
Apr 1, 2020 01:00PM Phase 3 Clinical Trial of Tedopi®: OSE Immunotherapeutics Announces Positive Top-Line Results for Step-1 of its trial ‘Atalante 1’ in Non-Small Cell Lung Cancer
Apr 1, 2020 12:00PM Phase 3 Clinical Trial of Tedopi®: OSE Immunotherapeutics Announces Positive Top-Line Results for Step-1 of its trial ‘Atalante 1’ in Non-Small Cell Lung Cancer
Mar 26, 2020 01:00PM OSE Immunotherapeutics Reports 2019 Financial Results And Provides Business Update
Mar 26, 2020 01:00PM OSE Immunotherapeutics Reports 2019 Financial Results and Provides Business Update Expectations for Potential Impact of COVID-19 on the Company’s Clinical Development Activities
Mar 17, 2020 01:08PM OSE Immunotherapeutics And Servier Amend the Global Licensing Option Agreement For IL-7R Antagonist OSE-127 in Autoimmune Diseases
Mar 17, 2020 01:00PM OSE Immunotherapeutics and Servier Amend the Global Licensing Option Agreement for IL-7R Antagonist OSE-127 in Autoimmune Diseases
Feb 12, 2020 12:00PM OSE Immunotherapeutics Announces Artificial Intelligence Antibody Drug Development Collaboration with MAbSilico
Feb 12, 2020 12:00PM OSE Immunotherapeutics Announces Artificial Intelligence Antibody Drug Development Collaboration with MAbSilico
Jan 14, 2020 02:00AM OSE Immunotherapeutics Announces Issuance of a New Patent in Japan for Tedopi® on Inducing Early T-Lymphocyte Memory Response
Jan 14, 2020 02:00AM OSE Immunotherapeutics Announces Issuance of a New Patent in Japan for Tedopi® on Inducing Early T-Lymphocyte Memory Response
Dec 2, 2019 12:00PM OSE Immunotherapeutics Announces Positive Results from Phase 1 Clinical Study of Anti-IL-7 Receptor Antagonist OSE-127
Dec 2, 2019 12:00PM OSE Immunotherapeutics Announces Positive Results from Phase 1 Clinical Study of Anti-IL-7 Receptor Antagonist OSE-127
Nov 27, 2019 12:00PM OSE Immunotherapeutics and HalioDx Collaborate to Perform Immune Biomarker Exploratory Work during Atalante 1 Phase 3 Clinical Trial of Tedopi® in Non-Small Cell Lung Cancer
Nov 27, 2019 12:00PM OSE Immunotherapeutics and HalioDx Collaborate to Perform Immune Biomarker Exploratory Work during Atalante 1 Phase 3 Clinical Trial of Tedopi® in Non-Small Cell Lung Cancer
Nov 11, 2019 02:00AM OSE Immunotherapeutics Presented Positive Correlation Between Neoepitope Response and Increased Survival for NSCLC Patients Treated with Tedopi®
Nov 11, 2019 02:00AM OSE Immunotherapeutics Presented Positive Correlation Between Neoepitope Response and Increased Survival for NSCLC Patients Treated with Tedopi®
Nov 7, 2019 12:00PM OSE Immunotherapeutics Announces Licensing Deal for Neoepitope Combination Tedopi® in Korea with Chong Kun Dang Pharmaceutical Corporation
Nov 7, 2019 12:00PM OSE Immunotherapeutics Announces Licensing Deal for Neoepitope Combination Tedopi® in Korea with Chong Kun Dang Pharmaceutical Corporation
Sep 30, 2019 02:00AM OSE Immunotherapeutics Presents New Preclinical Data on its Novel Bispecific Checkpoint Inhibitor (BiCKI®) Platform Targeting PD-1 and Cytokines To Overcome Tumor Resistance to Checkpoint Inhibitor B
Sep 30, 2019 02:00AM OSE Immunotherapeutics Presents New Preclinical Data on its Novel Bispecific Checkpoint Inhibitor (BiCKI®) Platform Targeting PD-1 and Cytokines to Overcome Tumor Resistance to Checkpoint Inhibitor B
Sep 18, 2019 12:36PM OSE Immunotherapeutics Receives a Milestone Payment of €5.4 Million From Bpifrance for SIRPα-Antagonist Monoclonal Antibody BI 765063
Sep 18, 2019 12:15PM OSE Immunotherapeutics Receives a Milestone Payment of €5.4 Million From Bpifrance for SIRPα-Antagonist Monoclonal Antibody BI 765063
Sep 5, 2019 12:00PM OSE Immunotherapeutics Reports First Half 2019 Results and Provides a Corporate Update
Sep 5, 2019 12:00PM OSE Immunotherapeutics Reports First Half 2019 Results and Provides a Corporate Update
Sep 3, 2019 12:00PM OSE Immunotherapeutics Receives New European Patent Protection Through 2037 for OSE-703, a Cytotoxic Monoclonal Antibody Targeting IL-7R, in Cancer Patients
Sep 3, 2019 12:00PM OSE Immunotherapeutics Receives New European Patent Protection Through 2037 for OSE-703, a Cytotoxic Monoclonal Antibody Targeting IL-7R, in Cancer Patients
Jul 23, 2019 12:00PM OSE Immunotherapeutics Receives a Grant from the French National Research Agency to Validate New Targets Linked to Myeloid Cells And Identify Innovative New Immunotherapies in Oncology
Jul 23, 2019 12:00PM OSE Immunotherapeutics Receives a Grant from the French National Research Agency to Validate New Targets Linked to Myeloid Cells And Identify Innovative New Immunotherapies in Oncology
Jul 17, 2019 01:00AM First Publication from OSE Immunotherapeutics on the Role of SIRPα in the Induction and Maintenance of Immune Tolerance in the American Journal of Transplantation
Jul 17, 2019 01:00AM First Publication from OSE Immunotherapeutics on the Role of SIRPα in the Induction and Maintenance of Immune Tolerance in the American Journal of Transplantation
Jul 10, 2019 12:15PM OSE Immunotherapeutics Receives Special Recognition for European Growth, Healthcare Enterprise and Women Entrepreneurship
Jul 10, 2019 12:07PM OSE Immunotherapeutics Receives Special Recognition for European Growth, Healthcare Enterprise and Women Entrepreneurship
Jun 26, 2019 12:30PM OSE Immunotherapeutics Announces Results of 2019 Annual Shareholder Meeting
Jun 26, 2019 12:30PM OSE Immunotherapeutics Announces Results of 2019 Annual Shareholder Meeting
Jun 24, 2019 01:00AM OSE Immunotherapeutics Will Participate in HealthTech Investor Days (HTID)
Jun 24, 2019 01:00AM OSE Immunotherapeutics Will Participate in HealthTech Investor Days (HTID)
Jun 20, 2019 12:00PM OSE Immunotherapeutics: Continuation of “Atalante 1” Phase 3 Clinical Trial of Tedopi® in NSCLC Patients Post Checkpoint Inhibitor Failure Following IDMC Recommendation
Jun 20, 2019 12:00PM Continuation of “Atalante 1” Phase 3 Clinical Trial of Tedopi® in NSCLC Patients Post Checkpoint Inhibitor Failure Following IDMC Recommendation
Jun 17, 2019 12:00PM Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient in a Phase 1 Trial of SIRPα Antagonist Monoclonal Antibody, BI 765063, in Patients with Advanced Solid Tumors
Jun 17, 2019 12:00PM Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient in a Phase 1 Trial of SIRPα Antagonist Monoclonal Antibody, BI 765063, in Patients with Advanced Solid Tumors
View More Recent Stories View Older Stories